| Maintenance therapy with certolizumab pegol for Crohn's disease S Schreiber, M Khaliq-Kareemi, IC Lawrance, OØ Thomsen, SB Hanauer, ... New England Journal of Medicine 357 (3), 239-250, 2007 | 1279 | 2007 |
| Multiple common variants for celiac disease influencing immune gene expression PCA Dubois, G Trynka, L Franke, KA Hunt, J Romanos, A Curtotti, ... Nature genetics 42 (4), 295-302, 2010 | 1218 | 2010 |
| Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin E Kenny-Walsh New England Journal of Medicine 340 (16), 1228-1233, 1999 | 1166 | 1999 |
| A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21 DA Van Heel, L Franke, KA Hunt, R Gwilliam, A Zhernakova, M Inouye, ... Nature genetics 39 (7), 827-829, 2007 | 849 | 2007 |
| Newly identified genetic risk variants for celiac disease related to the immune response KA Hunt, A Zhernakova, G Turner, GAR Heap, L Franke, M Bruinenberg, ... Nature genetics 40 (4), 395-402, 2008 | 845 | 2008 |
| Statistical methods for analysis of high-throughput RNA interference screens A Birmingham, LM Selfors, T Forster, D Wrobel, CJ Kennedy, E Shanks, ... Nature methods 6 (8), 569-575, 2009 | 672 | 2009 |
| International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease DC Fajgenbaum, TS Uldrick, A Bagg, D Frank, D Wu, G Srkalovic, ... Blood, The Journal of the American Society of Hematology 129 (12), 1646-1657, 2017 | 512 | 2017 |
| The Neutrophil-Activating Protein (Hp-Nap) of Helicobacter pylori Is a Protective Antigen and a Major Virulence Factor B Satin, G Del Giudice, V Della Bianca, S Dusi, C Laudanna, F Tonello, ... The journal of experimental medicine 191 (9), 1467-1476, 2000 | 451 | 2000 |
| Nanodrug applications in photodynamic therapy E Paszko, C Ehrhardt, MO Senge, DP Kelleher, JV Reynolds Photodiagnosis and photodynamic therapy 8 (1), 14-29, 2011 | 448 | 2011 |
| High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy RJ Farrell, A Murphy, A Long, S Donnelly, A Cherikuri, D O'Toole, ... Gastroenterology 118 (2), 279-288, 2000 | 378 | 2000 |
| St John's wort increases expression of P‐glycoprotein: implications for drug interactions M Hennessy, D Kelleher, JP Spiers, M Barry, P Kavanagh, D Back, ... British journal of clinical pharmacology 53 (1), 75-82, 2002 | 361 | 2002 |
| Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source SM McKiernan, R Hagan, M Curry, GSA McDonald, A Kelly, N Nolan, ... Hepatology 40 (1), 108-114, 2004 | 342 | 2004 |
| Activated protein C inhibits lipopolysaccharide‐induced nuclear translocation of nuclear factor κB (NF‐κB) and tumour necrosis factor α (TNF‐α) production in the THP‐1 … B White, M Schmidt, C Murphy, W Livingstone, D O'toole, M Lawler, ... British journal of haematology 110 (1), 130-134, 2000 | 326 | 2000 |
| Idiopathic multicentric Castleman's disease: a systematic literature review AY Liu, CS Nabel, BS Finkelman, JR Ruth, R Kurzrock, F van Rhee, ... The Lancet Haematology 3 (4), e163-e175, 2016 | 300 | 2016 |
| Nonfunctionalized nanocrystals can exploit a cell's active transport machinery delivering them to specific nuclear and cytoplasmic compartments I Nabiev, S Mitchell, A Davies, Y Williams, D Kelleher, R Moore, ... Nano letters 7 (11), 3452-3461, 2007 | 295 | 2007 |
| Glucocorticoid resistance in inflammatory bowel disease. RJ Farrell, D Kelleher The Journal of endocrinology 178 (3), 339-346, 2003 | 293 | 2003 |
| Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low RJ Farrell, Y Ang, P Kileen, DS O'briain, D Kelleher, PWN Keeling, ... Gut 47 (4), 514-519, 2000 | 274 | 2000 |
| Protein kinase C and the cytoskeleton C Keenan, D Kelleher Cellular signalling 10 (4), 225-232, 1998 | 268 | 1998 |
| Dominant influence of an HLA‐B27 restricted CD8+ T cell response in mediating HCV clearance and evolution C Neumann‐Haefelin, S McKiernan, S Ward, S Viazov, HC Spangenberg, ... Hepatology 43 (3), 563-572, 2006 | 263 | 2006 |
| Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data S Schreiber, JF Colombel, R Bloomfield, S Nikolaus, J Schölmerich, ... Official journal of the American College of Gastroenterology| ACG 105 (7 …, 2010 | 261 | 2010 |
Ross McManusProfessor of Molecular Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College在 tcd.ie 的电子邮件经过验证
